Skip to content

A clinical study to assess the safety and effectiveness of test product “Moiz Cleansing Lotion ? in healthy adult human subjects with varied skin types.

An Exploratory, Prospective, Open-Label, Interventional, Safety In-Use, Tolerability and Efficacy Study of Test Product “Moiz Cleansing Lotion ? in Healthy Human Subjects. - Nil

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/10/075297
Enrollment
27
Registered
2024-10-15
Start date
Unknown
Completion date
Unknown
Last updated
2024-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Test Product Name- Moiz Cleansing Lotion: Mode of Usage: Apply 5-10 ml of Moiz Cleansing Lotion to wet skin. Massage gently for 1-2 minutes, then rinse and pat dry. Frequency: Twice a D

Sponsors

Glowderma Lab Private Limited
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1) Age: 18 to 65 years (both inclusive) at the time of consent. 2) Sex: Healthy male and non-pregnant/non-lactating females (Preferably equal). 3) Females of childbearing potential must have a self-reported negative pregnancy test. 4) Subject are generally in good health. 5) Subject with dry, oily, mixed, sensitive and normal skin at a time of screening. (Dermatological Assessment) 6) Subjects forearm must be free of cuts, tattoos, scratches, abrasions, scars, uneven skin tone, sunburn, excessive tan, excessive hair or open wounds on or near the test sites 7) Subject is able to remain on stable doses of contraceptive or replacement hormonal therapy, including no therapy, 6 weeks prior to and for the duration of the study. 8) If the subject is of childbearing potential, is practicing and agrees to maintain an established method of birth control (IUD, hormonal implant device/injection, regular use of birth control pills or patch, diaphragm, condoms with spermicide or sponge with spermicidal jelly, cream or foam, partner vasectomy or abstinence). Females will be considered as non-childbearing potential if they are surgically sterile, have been post-menopausal for at least 1 year or have had a tubal ligation. 9) Subjects are willing to give written informed consent and are willing to come for regular follow up. 10) Subjects who commit not to use medicated skincare products other than the test product for the entire duration of the study. 11) Subject who have not participated in a similar investigation in the past three months. 12) Willing to use test product throughout the study period.

Exclusion criteria

Exclusion criteria: 1) History of any dermatological condition of the skin diseases. 2) Subject with present condition of allergic response to any cosmetic product. 3) Subject having allergic response to the ink. 4) Subjects under chronic medication (e.g. aspirin-based products, anti-inflammatories, anti-histamines, corticotherapy etc.) that might influence the outcome of the study. 5) Subject having acne of severe incidence (presence of nodules, cysts or numerous pustules) which requires pharmaceutical or cosmeceuticals, herbal product. 6) Subjects who have applied topical product for at least 4 weeks and any systemic product for at least 3 months, before they participated in the study. 7) History of alcohol or drug addiction. 8) Subjects using other marketed products during the study period. 9) Any other condition which could warrant exclusion from the study, as per the dermatologist’s/investigator’s discretion. 10) Pregnant or breastfeeding or planning to become pregnant during the study period. 11) History of chronic illness which may influence the cutaneous state. 12) Subjects participating in other similar cosmetics, devices or therapeutic trials or skincare products within the last four weeks.

Design outcomes

Primary

MeasureTime frame
1.To evaluate the effectiveness of the test product in terms of change in L, a, b value. 2. To evaluate the effectiveness of the test product in terms of change in skin impurities.Timepoint: from baseline before usage of the test product on Day 01 and after usage of the test product at T20 mins on Day 01, Day 15 and Day 30 by using Skin Colorimeter.

Secondary

MeasureTime frame
To evaluate the effectiveness of the test product in terms of change in 1. skin hydration 2. skin barrier function 3. overall dry skin score 4. PGA score 5. visual and tactile assessment 6. product perception questionnaire 7. Safety of the test product will be evaluated in terms of change in skin irritation, dryness, breakouts, allergic reactionsTimepoint: from baseline before usage of the test product on Day 01 and after usage of the test product at T20 mins on Day 01, Day 15 and Day 30 .

Countries

India

Contacts

Public ContactMaheshvari Patel

NovoBliss Research Private Limited

dr.nayan@novobliss.in9909013286

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026